Stock PYC PYC THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Market Closed - Australian S.E.
Other stock markets
 02:10:22 2024-05-23 am EDT 		5-day change 1st Jan Change
0.12 AUD +14.29% Intraday chart for PYC Therapeutics Limited +23.71% +9.09%
May. 16 PYC Therapeutics Completes Dosing for Eye Disease Trial; Shares Fall 5% MT
May. 09 Transcript : PYC Therapeutics Limited - Special Call

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PYC THERAPEUTICS LIMITED Stock PYC Therapeutics Limited
+9.09% 325M -
MODERNA, INC. Stock Moderna, Inc.
+64.23% 62.59B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.31% 41.18B
B
LONZA GROUP AG Stock Lonza Group AG
+45.04% 40.29B
A
CELLTRION, INC. Stock Celltrion, Inc.
-8.29% 27.9B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.97% 26.21B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.16% 19.09B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+7.54% 13.08B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.17% 12.05B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.72% 12.26B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PYC Stock
  4. Ratings PYC Therapeutics Limited